EP2908853 - THY1 (CD90) AS A THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION [Right-click to bookmark this link] | |||
Former [2015/35] | THY1 (CD90) AS A NOVEL THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION | ||
[2018/19] | Status | No opposition filed within time limit Status updated on 11.10.2019 Database last updated on 09.09.2024 | |
Former | The patent has been granted Status updated on 02.11.2018 | ||
Former | Grant of patent is intended Status updated on 10.05.2018 | ||
Former | Examination is in progress Status updated on 03.02.2017 | Most recent event Tooltip | 01.07.2022 | Lapse of the patent in a contracting state New state(s): MK | published on 03.08.2022 [2022/31] | Applicant(s) | For all designated states University of Rochester 601 Elmwood Avenue Box OTT Rochester, NY 14642 / US | [2015/35] | Inventor(s) | 01 /
PHIPPS, Richard, P. 26 Greylock Ridge Pittsford, NY 14534 / US | 02 /
WOELLER, Collynn, F. 920 Blackcherry Lane Webster, NY 14580 / US | 03 /
FELDON, Steven, E. 39 Sandringham Road Rocherster, NY 14610 / US | [2015/35] | Representative(s) | Adamson Jones Park View House 58 The Ropewalk Nottingham NG1 5DW / GB | [N/P] |
Former [2015/35] | Adamson Jones BioCity Nottingham Pennyfoot Street Nottingham NG1 1GF / GB | Application number, filing date | 13847469.7 | 21.10.2013 | [2015/35] | WO2013US65952 | Priority number, date | US201261716558P | 21.10.2012 Original published format: US 201261716558 P | [2015/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014063155 | Date: | 24.04.2014 | Language: | EN | [2014/17] | Type: | A1 Application with search report | No.: | EP2908853 | Date: | 26.08.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.04.2014 takes the place of the publication of the European patent application. | [2015/35] | Type: | B1 Patent specification | No.: | EP2908853 | Date: | 05.12.2018 | Language: | EN | [2018/49] | Search report(s) | International search report - published on: | US | 24.04.2014 | (Supplementary) European search report - dispatched on: | EP | 15.04.2016 | Classification | IPC: | A61K38/17, C07K14/705 | [2016/20] | CPC: |
C12N15/1138 (EP,US);
A61K38/177 (US);
A61K38/1774 (EP,US);
A61K9/0014 (US);
A61K9/0048 (US);
C07K14/70503 (EP,US);
|
Former IPC [2015/35] | A61K39/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/35] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | THY1 (CD90) ALS THERAPIE ZUR STEUERUNG VON FETTGEWEBEAKKUMULATION | [2018/19] | English: | THY1 (CD90) AS A THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION | [2018/19] | French: | THY1 (CD90) EN TANT QUE THÉRAPIE POUR RÉGULER L'ACCUMULATION DE TISSU ADIPEUX | [2018/19] |
Former [2015/35] | THY1 (CD90) ALS NEUARTIGE THERAPIE ZUR STEUERUNG VON FETTGEWEBEAKKUMULATION | ||
Former [2015/35] | THY1 (CD90) AS A NOVEL THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION | ||
Former [2015/35] | THY1 (CD90) EN TANT QUE NOUVELLE THÉRAPIE POUR RÉGULER L'ACCUMULATION DE TISSU ADIPEUX | Entry into regional phase | 08.05.2015 | National basic fee paid | 08.05.2015 | Search fee paid | 08.05.2015 | Designation fee(s) paid | 08.05.2015 | Examination fee paid | Examination procedure | 08.05.2015 | Examination requested [2015/35] | 11.11.2016 | Amendment by applicant (claims and/or description) | 01.02.2017 | Despatch of a communication from the examining division (Time limit: M06) | 07.08.2017 | Reply to a communication from the examining division | 16.11.2017 | Despatch of a communication from the examining division (Time limit: M04) | 21.03.2018 | Reply to a communication from the examining division | 11.05.2018 | Communication of intention to grant the patent | 20.09.2018 | Fee for grant paid | 20.09.2018 | Fee for publishing/printing paid | 20.09.2018 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 01.02.2017 | Opposition(s) | 06.09.2019 | No opposition filed within time limit [2019/46] | Fees paid | Renewal fee | 27.10.2015 | Renewal fee patent year 03 | 27.10.2016 | Renewal fee patent year 04 | 27.10.2017 | Renewal fee patent year 05 | 29.10.2018 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 21.10.2013 | AL | 05.12.2018 | AT | 05.12.2018 | CY | 05.12.2018 | CZ | 05.12.2018 | DK | 05.12.2018 | EE | 05.12.2018 | ES | 05.12.2018 | FI | 05.12.2018 | HR | 05.12.2018 | IT | 05.12.2018 | LT | 05.12.2018 | LV | 05.12.2018 | MC | 05.12.2018 | MK | 05.12.2018 | MT | 05.12.2018 | NL | 05.12.2018 | PL | 05.12.2018 | RO | 05.12.2018 | RS | 05.12.2018 | SE | 05.12.2018 | SI | 05.12.2018 | SK | 05.12.2018 | SM | 05.12.2018 | TR | 05.12.2018 | BG | 05.03.2019 | NO | 05.03.2019 | GR | 06.03.2019 | IS | 05.04.2019 | PT | 05.04.2019 | [2022/31] |
Former [2021/34] | HU | 21.10.2013 | |
AL | 05.12.2018 | ||
AT | 05.12.2018 | ||
CY | 05.12.2018 | ||
CZ | 05.12.2018 | ||
DK | 05.12.2018 | ||
EE | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
MC | 05.12.2018 | ||
MT | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RO | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
SI | 05.12.2018 | ||
SK | 05.12.2018 | ||
SM | 05.12.2018 | ||
TR | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
IS | 05.04.2019 | ||
PT | 05.04.2019 | ||
Former [2021/33] | HU | 21.10.2013 | |
AL | 05.12.2018 | ||
AT | 05.12.2018 | ||
CY | 05.12.2018 | ||
CZ | 05.12.2018 | ||
DK | 05.12.2018 | ||
EE | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
MC | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RO | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
SI | 05.12.2018 | ||
SK | 05.12.2018 | ||
SM | 05.12.2018 | ||
TR | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
IS | 05.04.2019 | ||
PT | 05.04.2019 | ||
Former [2021/26] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
CY | 05.12.2018 | ||
CZ | 05.12.2018 | ||
DK | 05.12.2018 | ||
EE | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
MC | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RO | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
SI | 05.12.2018 | ||
SK | 05.12.2018 | ||
SM | 05.12.2018 | ||
TR | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
IS | 05.04.2019 | ||
PT | 05.04.2019 | ||
Former [2020/29] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
CZ | 05.12.2018 | ||
DK | 05.12.2018 | ||
EE | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
MC | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RO | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
SI | 05.12.2018 | ||
SK | 05.12.2018 | ||
SM | 05.12.2018 | ||
TR | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
IS | 05.04.2019 | ||
PT | 05.04.2019 | ||
Former [2020/17] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
CZ | 05.12.2018 | ||
DK | 05.12.2018 | ||
EE | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RO | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
SI | 05.12.2018 | ||
SK | 05.12.2018 | ||
SM | 05.12.2018 | ||
TR | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
IS | 05.04.2019 | ||
PT | 05.04.2019 | ||
Former [2019/50] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
CZ | 05.12.2018 | ||
DK | 05.12.2018 | ||
EE | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RO | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
SI | 05.12.2018 | ||
SK | 05.12.2018 | ||
SM | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
IS | 05.04.2019 | ||
PT | 05.04.2019 | ||
Former [2019/48] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
CZ | 05.12.2018 | ||
DK | 05.12.2018 | ||
EE | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RO | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
SK | 05.12.2018 | ||
SM | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
IS | 05.04.2019 | ||
PT | 05.04.2019 | ||
Former [2019/39] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
CZ | 05.12.2018 | ||
EE | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RO | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
SK | 05.12.2018 | ||
SM | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
IS | 05.04.2019 | ||
PT | 05.04.2019 | ||
Former [2019/37] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
CZ | 05.12.2018 | ||
EE | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RO | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
SM | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
PT | 05.04.2019 | ||
Former [2019/35] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
CZ | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
NL | 05.12.2018 | ||
PL | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
PT | 05.04.2019 | ||
Former [2019/34] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
IT | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
NL | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
PT | 05.04.2019 | ||
Former [2019/33] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
NL | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
PT | 05.04.2019 | ||
Former [2019/30] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
NL | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
Former [2019/26] | AL | 05.12.2018 | |
AT | 05.12.2018 | ||
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
Former [2019/25] | AT | 05.12.2018 | |
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
RS | 05.12.2018 | ||
SE | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
Former [2019/24] | AT | 05.12.2018 | |
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
SE | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
GR | 06.03.2019 | ||
Former [2019/23] | AT | 05.12.2018 | |
ES | 05.12.2018 | ||
FI | 05.12.2018 | ||
HR | 05.12.2018 | ||
LT | 05.12.2018 | ||
LV | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
Former [2019/22] | FI | 05.12.2018 | |
LT | 05.12.2018 | ||
BG | 05.03.2019 | ||
NO | 05.03.2019 | ||
Former [2019/21] | FI | 05.12.2018 | |
LT | 05.12.2018 | ||
NO | 05.03.2019 | ||
Former [2019/20] | LT | 05.12.2018 | |
NO | 05.03.2019 | Documents cited: | Search | [X]WO9945951 (HARVARD COLLEGE [US], et al) [X] 10-15 * page 1, line 32 - page 5, line 24 * * page 13, line 23 - page 14, line 10 *; | [XI]WO2010133970 (ETH ZUERICH [CH], et al) [X] 1,3,5,8,9,16,17 * the whole document * [I] 6,7; | [X]WO2011119199 (EINSTEIN COLL MED [US], et al) [X] 1,3,8,9 * paragraphs [0014] , [0041] , [0042] , [0045] , [0046] , [0049] , [0050] , [0071] , [0072] *; | [X] - M. DEVASAHAYAM ET AL, "The glycan processing and site occupancy of recombinant Thy-1 is markedly affected by the presence of a glycosylphosphatidylinositol anchor", GLYCOBIOLOGY, US, (19991201), vol. 9, no. 12, doi:10.1093/glycob/9.12.1381, ISSN 0959-6658, pages 1381 - 1387, XP055263782 [X] 10-15 * abstract * * page 1383, column r * * page 1385, column r, paragraph l - page 1386, column l, paragraph 1 * DOI: http://dx.doi.org/10.1093/glycob/9.12.1381 | [A] - BRIAN M. VARISCO ET AL, "Thy-1 Signals through PPAR[gamma] to Promote Lipofibroblast Differentiation in the Developing Lung", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY., NEW YORK, NY, US, (20120601), vol. 46, no. 6, doi:10.1165/rcmb.2011-0316OC, ISSN 1044-1549, pages 765 - 772, XP055263762 [A] 1,10 * abstract * DOI: http://dx.doi.org/10.1165/rcmb.2011-0316OC | International search | [X]US2004266993 (EVANS GLEN A [US]); | [Y]US2012015001 (PHIPPS RICHARD P [US], et al); | [X] - LEHMANN ET AL., "Novel anti-adipogenic activity produced by human fibroblasts.", AM J PHYSIOL CELL PHYSIOL., (201009), vol. 299, no. 3, pages C672 - C681, XP055251598 DOI: http://dx.doi.org/10.1152/ajpcell.00451.2009 | [Y] - TRAJKOVSKI ET AL., "MICRORNAS 103 AND 107 REGULATE INSULIN SENSITIVITY.", NATURE, (20110608), vol. 474, no. 7353, pages 649 - 653, XP055222703 DOI: http://dx.doi.org/10.1038/nature10112 | by applicant | US4237224 | US5059421 | US5138045 | WO9306223 | WO9307283 | WO9307282 | US5214136 | US5407926 | US5631237 | US5643599 | US5653996 | US5681811 | US5849586 | US5871727 | US5885613 | US5885808 | US5981225 | US5994132 | US6001557 | US6033908 | US6057155 | US6060463 | US6074673 | US6149935 | US6153737 | US6210717 | WO0130337 | US6235886 | WO0168053 | US6335434 | US6464687 | US6528631 | WO2004043480 | WO2004058289 | US2004147026 | US2004170962 | US6790657 | US6835718 | US2005101582 | WO2006015299 | WO2006044206 | EP1674068 | WO2006091297 | US2008118500 | WO2008151639 | US2009036552 | US2010286378 | WO2011117353 | US2011245481 | WO2012069059 | US2012245219 | - JUONALA et al., "Childhood Adiposity, Adult Adiposity, and Cardiovascular Risk Factors", N Engl J Med, (20110000), vol. 365, no. 20, pages 1876 - 85 | - LUDWIG, D.S., "Childhood Obesity--the Shape of Things to Come", N Engl J Med, (20070000), vol. 357, no. 23, pages 2325 - 7 | - TROSKO et al., "Factors to Consider in the Use of Stem Cells for Pharmaceutic Drug Development and for Chemical Safety Assessment", Toxicology, (20100000), vol. 270, no. 1, pages 18 - 34, XP026982363 | - JANESICK et al., "Endocrine Disrupting Chemicals and the Developmental Programming of Adipogenesis and Obesity", Birth Defects Res C Embryo Today, (20110000), vol. 93, no. 1, pages 34 - 50 | - GRUN et al., "Environmental Obesogens: Organotins and Endocrine Disruption Via Nuclear Receptor Signaling", Endocrinology, (20060000), vol. 147, no. 6, pages S50 - 5 | - JANESICK et al., "Obesogens, Stem Cells and the Developmental Programming of Obesity", Int JAndrol, (20120000), vol. 35, no. 3, pages 437 - 48 | - BOEKELHEIDE et al., "Predicting Later-Life Outcomes of Early-Life Exposures", Environ Health Perspect, (20120000), vol. 120, no. 10, pages 1353 - 61 | - BAHN, R.S., "Graves' Ophthalmopathy", N Engl J Med, (20100000), vol. 362, no. 8, pages 726 - 38 | - KURIYAN et al., "The Eye and Thyroid Disease", Curr Opin Ophthalmol, (20080000), vol. 19, no. 6, pages 499 - 506 | - LEHMANN et al., "Novel Anti-adipogenic Activity Produced by Human Fibroblasts", Am J Physiol Cell Physiol, (20100000), vol. 299, no. 3, doi:doi:10.1152/ajpcell.00451.2009, pages C672 - 81, XP055251598 DOI: http://dx.doi.org/10.1152/ajpcell.00451.2009 | - TRAJKOVSKI et al., "MicroRNAs 103 and 107 Regulate Insulin Sensitivity", Nature, (20110000), vol. 474, no. 7353, doi:doi:10.1038/nature10112, pages 649 - 53, XP055222703 DOI: http://dx.doi.org/10.1038/nature10112 | - SANDERS et al., "Epigenetic Regulation of Thy-1 by Histone Deacetylase Inhibitor in Rat Lung Fibroblasts", Am J Respir Cell Mol Biol, (20110000), vol. 45, no. 1, pages 16 - 23 | - PHIPPS et al., "Characterization of Two Major Populations of Lung Fibroblasts: Distinguishing Morphology and Discordant Display of Thy 1 and Class II MHC", Am JRespir Cell Mol Biol, (19890000), vol. 1, no. 1, pages 65 - 74 | - BAGLOLE et al., "More Than Structural Cells, Fibroblasts Create and Orchestrate the Tumor Microenvironment", Immunol Invest, (20060000), vol. 35, no. 3-4, pages 297 - 325 | - BRADLEY et al., "Roles and Regulation of Thyl, a Context-Dependent Modulator of Cell Phenotype", Biofactors, (20090000), vol. 35, no. 3, pages 258 - 65 | - PEI et al., "Thy-1 Distinguishes Human Corneal Fibroblasts and Myofibroblasts from Keratocytes", Exp Eye Res, (20040000), vol. 79, no. 5, doi:doi:10.1016/j.exer.2004.08.002, pages 705 - 12, XP004608949 DOI: http://dx.doi.org/10.1016/j.exer.2004.08.002 | - KOUMAS et al., "Thy-1 Expression in Human Fibroblast Subsets Defines Myofibroblastic or Lipofibroblastic Phenotypes", Am J Pathol, (20030000), vol. 163, no. 4, pages 1291 - 300 | - KOUMAS et al., "Fibroblast Subsets in the Human Orbit: Thy-1+ and Thy-1-Subpopulations Exhibit Distinct Phenotypes", Eur J Immunol, (20020000), vol. 32, no. 2, pages 477 - 85 | - GUO et al., "Mast Cell-Derived Prostaglandin D2 Controls Hyaluronan Synthesis in Human Orbital Fibroblasts Via Dpi Activation: Implications for Thyroid Eye Disease", J Biol Chem, (20100000), vol. 285, no. 21, pages 15794 - 804 | - KOO et al., "Fyn Inhibition by Cycloalkane-Fused 1,2-Dithiole-3-thiones Enhances Antioxidant Capacity and Protects Mitochondria from Oxidative Injury", Mol Pharmacol, (20120000), vol. 82, pages 27 - 36 | - WANG et al., "Identification and Characterization of a Promoter Cassette Conferring Adipocyte-specific Gene Expression", Endocrinol, (20100000), vol. 151, no. 6, pages 2933 - 9 | - KURLAWALLA-MARTINEZ et al., "Insulin Hypersensitivity and Resistance to Streptozotocin-induced Diabetes in Mice Lacking PTEN in Adipose Tissue", Mol Cell Biol., (20050000), vol. 25, no. 6, pages 2498 - 2510 | - ROBERTS; LAUER, "Maximizing Gene Expression On a Plasmid Using Recombination In Vitro", Methods in Enzymology, (19790000), vol. 68, pages 473 - 82, XP001314595 | - Proc. Natl. Acad. Sci. USA, (19870000), vol. 84, page 7851 | - Biochemistry, (19890000), vol. 28, page 908 | - BANGHAM et al., J. Mol. Biol., (19650000), vol. 13, pages 238 - 252 | - BERKNER, Biotechniques, (19880000), vol. 6, pages 616 - 627 | - ROSENFELD et al., Science, (19910000), vol. 252, pages 431 - 434 | - CHATTERJEE et al., Science, (19920000), vol. 258, pages 1485 - 1488 | - WALSH et al., Proc. Nat'lAcad. Sci. USA, (19920000), vol. 89, pages 7257 - 7261 | - WALSH et al., J. Clin. Invest., (19940000), vol. 94, pages 1440 - 1448 | - FLOTTE et al., J. Biol. Chem., (19930000), vol. 268, pages 3781 - 3790 | - PONNAZHAGAN et al., J. Exp. Med., (19940000), vol. 179, pages 733 - 738 | - MILLER et al., Proc. Nat'l Acad. Sci. USA, (19940000), vol. 91, pages 10183 - 10187 | - EINERHAND et al., Gene Ther., (19950000), vol. 2, pages 336 - 343 | - LUO et al., Exp. Hematol., (19950000), vol. 23, pages 1261 - 1267 | - ZHOU et al., Gene Ther., (19960000), vol. 3, pages 223 - 229 | - FLOTTE et al., Proc. Nat'l Acad. Sci. USA, (19930000), vol. 90, pages 10613 - 10617 | - KAPLITT et al., Nature Genet., (19940000), vol. 8, pages 148 - 153 | - KIM et al., "ADD1/SREBP1 Activates PPARgamma Through the Production of Endogenous Ligand", Proc Natl Acad Sci USA, (19980000), vol. 95, no. 8, pages 4333 - 7 | - FORMAN et al., "15-Deoxy-delta 12, 14-prostaglandin J2 is a Ligand for the Adipocyte Determination Factor PPARgamma", Cell, (19950000), vol. 83, no. 5, doi:doi:10.1016/0092-8674(95)90193-0, pages 803 - 12, XP002935823 DOI: http://dx.doi.org/10.1016/0092-8674(95)90193-0 | - CHEN et al., "Krox20 Stimulates Adipogenesis Via C/Ebpbeta-Dependent and -Independent Mechanisms", Cell Metab, (20050000), vol. 1, no. 2, pages 93 - 106 | - GRONTVED et al., "Medl4 Tethers Mediator to the N-Terminal Domain of Peroxisome Proliferator-Activated Receptor Gamma and Is Required for Full Transcriptional Activity and Adipogenesis", Mol Cell Biol, (20100000), vol. 30, no. 9, pages 2155 - 69 | - JUNG et al., "Peroxisome Proliferator-Activated Receptor Gamma/Signal Transducers and Activators of Transcription 5a Pathway Plays a Key Factor in Adipogenesis of Human Bone Marrow-Derived Stromal Cells and 3t3-Ll Preadipocytes", Stem Cells Dev, (20110000), vol. 21, no. 3, pages 465 - 75 | - PANTOJA et al., "Glucocorticoid Signaling Defines a Novel Commitment State During Adipogenesis in Vitro", Mol Biol Cell, (20080000), vol. 19, no. 10, pages 4032 - 41 | - ROSS et al., "Dual Roles for the Notch Target Gene Hes-1 in the Differentiation of 3t3-Ll Preadipocytes", Mol Cell Biol, (20040000), vol. 24, no. 8, doi:doi:10.1128/MCB.24.8.3505-3513.2004, pages 3505 - 13, XP055015041 DOI: http://dx.doi.org/10.1128/MCB.24.8.3505-3513.2004 | - SARRUF et al., "Cyclin D3 Promotes Adipogenesis through Activation of Peroxisome Proliferator-Activated Receptor Gamma", Mol Cell Biol, (20050000), vol. 25, no. 22, pages 9985 - 95 | - XUE et al., "Distinct Stages in Adipogenesis Revealed by Retinoid Inhibition of Differentiation after Induction of PPARgamma", Mol Cell Biol, (19960000), vol. 16, no. 4, pages 1567 - 75, XP000577882 | - YING et al., "Impaired Adipogenesis Caused by a Mutated Thyroid Hormone Alphal Receptor", Mol Cell Biol, (20070000), vol. 27, no. 6, pages 2359 - 71 | - RIU et al., "Peroxisome Proliferator-Activated Receptor Gamma is a Target for Halogenated Analogs of Bisphenol A", Environ Health Perspect, (20110000), vol. 119, no. 9, pages 1227 - 32 | - KIRCHNER et al., "Prenatal Exposure to the Environmental Obesogen Tributyltin Predisposes Multipotent Stem Cells to Become Adipocytes", Mol Endocrinol, (20100000), vol. 24, no. 3, pages 526 - 39 | - GRUN et al., "Endocrine-Disrupting Organotin Compounds are Potent Inducers of Adipogenesis in Vertebrates", Mol Endocrinol, (20060000), vol. 20, no. 9, pages 2141 - 55 | - ANTIZAR-LADISLAO, B, "Environmental Levels, Toxicity and Human Exposure to Tributyltin (TBT)-Contaminated Marine Environment. A Review", Environ Int, (20080000), vol. 34, no. 2, doi:doi:10.1016/j.envint.2007.09.005, pages 292 - 308, XP029235019 DOI: http://dx.doi.org/10.1016/j.envint.2007.09.005 | - BARTEL, D.P., "MicroRNAS: Target Recognition and Regulatory Functions", Cell, (20090000), vol. 136, no. 2, doi:doi:10.1016/j.cell.2009.01.002, pages 215 - 33, XP055011377 DOI: http://dx.doi.org/10.1016/j.cell.2009.01.002 | - FURER et al., "The Role of MicroRNA in Rheumatoid Arthritis and Other Autoimmune Diseases", Clin Immunol, (20100000), vol. 136, no. 1, doi:doi:10.1016/j.clim.2010.02.005, pages 1 - 15, XP027074866 DOI: http://dx.doi.org/10.1016/j.clim.2010.02.005 | - XIE et al., "MicroRNAS Induced During Adipogenesis That Accelerate Fat Cell Development Are Downregulated in Obesity", Diabetes, (20090000), vol. 58, no. 5, doi:doi:10.2337/db08-1299, pages 1050 - 7, XP002598120 DOI: http://dx.doi.org/10.2337/db08-1299 | - CROW, J.M., "Obesity: Insensitive Issue", Nature, (20120000), vol. 486, pages 12 - 13 | - HASLER et al., "A Functional Methylome Map of Ulcerative Colitis", Genome Res, (20120000), vol. 22, no. 11, pages 2137 - 7 | - GUO et al., "Mammalian MicroRNAs Predominantly Act to Decrease Target mRNA Levels", Nature, (20100000), vol. 466, doi:doi:10.1038/nature09267, pages 835 - 840, XP055326492 DOI: http://dx.doi.org/10.1038/nature09267 | - LEWIS et al., "Conserved Seed Pairing, Often Flanked by Adenosines, Indicates That Thousands of Human Genes are MicroRNA Targets", Cell, (20050000), vol. 120, pages 15 - 20 | - HAN; SMITH, "T Helper Type 1 and Type 2 Cytokines Exert Divergent Influence on the Induction of Prostaglandin E2 and Hyaluronan Synthesis by Interleukin-lbeta in Orbital Fibroblasts: Implications for the Pathogenesis of Thyroid-Associated Ophthalmopathy", Endocrinology, (20060000), vol. 147, no. 1, pages 13 - 9 | - REDFERN; MCDERMOTT, "Toll-Like Receptors in Ocular Surface Disease", Experimental Eye Research, (20100000), vol. 90, no. 6, pages 679 - 87, XP027051364 | - REDFERN et al., "Toll-Like Receptor Activation Modulates Antimicrobial Peptide Expression by Ocular Surface Cells", Experimental Eye Research, (20110000), vol. 92, no. 3, doi:doi:10.1016/j.exer.2010.12.005, pages 209 - 20, XP028186093 DOI: http://dx.doi.org/10.1016/j.exer.2010.12.005 | - SMITH et al., "Unique Attributes of Orbital Fibroblasts and Global Alterations in Igf-1 Receptor Signaling Could Explain Thyroid-Associated Ophthalmopathy", Thyroid, (20080000), vol. 18, no. 9, pages 983 - 8 | - FELDON et al., "Activated Human T Lymphocytes Express Cyclooxygenase-2 and Produce Proadipogenic Prostaglandins That Drive Human Orbital Fibroblast Differentiation to Adipocytes", Am J Pathol, (20060000), vol. 169, no. 4, pages 1183 - 93 | - PHIPPS et al., "Characterization of Two Major Populations of Lung Fibroblasts: Distinguishing Morphology and Discordant Display of Thy 1 and Class Ii Mhc", Am JRespir Cell Mol Biol, (19890000), vol. 1, no. 1, pages 65 - 74 | - KAMINSKI et al., "Susceptibility of Ocular Tissues to Autoimmune Diseases", Ann N YAcad Sci, (20030000), vol. 998, pages 362 - 74 | - KUMAR; BAHN, "Relative Overexpression of Macrophage-Derived Cytokines in Orbital Adipose Tissue from Patients with Graves' Ophthalmopathy", J Clin Endocrinol Metab, (20030000), vol. 88, no. 9, pages 4246 - 50 | - LEHMANN et al., "Immune Mechanisms in Thyroid Eye Disease", Thyroid, (20080000), vol. 18, no. 9, pages 959 - 65 | - BUJALSKA et al., "Characterisation of llbeta-Hydroxysteroid Dehydrogenase 1 in Human Orbital Adipose Tissue: A Comparison with Subcutaneous and Omental Fat", J Endocrinol, (20070000), vol. 192, no. 2, pages 279 - 88 | - LUDGATE; BAKER, "Unlocking the Immunological Mechanisms of Orbital Inflammation in Thyroid Eye Disease", Clin Exp Immunol, (20020000), vol. 127, no. 2, pages 193 - 8 | - PRABHAKAR et al., "Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy", Endocr Rev, (20030000), vol. 24, no. 6, pages 802 - 35 | - KOUMAS et al., "Fibroblast Heterogeneity: Existence of Functionally Distinct Thy 1(+) and Thy l(-) Human Female Reproductive Tract Fibroblasts", Am J Pathol, (20010000), vol. 159, no. 3, pages 925 - 35, XP001064501 | - SMITH et al., "Orbital Fibroblast Heterogeneity May Determine the Clinical Presentation of Thyroid-Associated Ophthalmopathy", J Clin Endocrinol Metab, (20020000), vol. 87, no. 1, pages 385 - 92 | - HWANG et al., "Orbital Fibroblasts from Patients with Thyroid-Associated Ophthalmopathy Overexpress Cd40: Cd154 Hyperinduces 11-6, 11-8, and Mcp-1", Invest Ophthalmol Vis Sci, (20090000), vol. 50, no. 5, pages 2262 - 8 | - RAYCHAUDHURI et al., "Pge2 Induces 11-6 in Orbital Fibroblasts through Ep2 Receptors and Increased Gene Promoter Activity: Implications to Thyroid-Associated Ophthalmopathy", PLoS One, (20100000), vol. 5, no. 12, page e15296 | - KOUMAS et al., "Thy-1 Expression in Human Fibroblast Subsets Defines Myofibroblastic or Lipofibroblastic Phenotypes", Am JPathol, (20030000), vol. 163, no. 4, pages 1291 - 300 | - LEHMANN et al., "Novel Anti-Adipogenic Activity Produced by Human Fibroblasts", Am J Physiol Cell Physiol, (20100000), vol. 299, no. 3, doi:doi:10.1152/ajpcell.00451.2009, pages C672 - C681, XP055251598 DOI: http://dx.doi.org/10.1152/ajpcell.00451.2009 | - BRADLEY et al., "Roles and Regulation of Thy-1, a Context-Dependent Modulator of Cell Phenotype", Biofactors, (20090000), vol. 35, no. 3, pages 258 - 65 | - KEMSHEAD et al., "Human Thy-1: Expression on the Cell Surface of Neuronal and Glial Cells", Brain Res, (19820000), vol. 236, no. 2, doi:doi:10.1016/0006-8993(82)90727-2, pages 451 - 61, XP024256495 DOI: http://dx.doi.org/10.1016/0006-8993(82)90727-2 | - COHEN et al., "Thyl up-Regulates Fasl Expression in Lung Myofibroblasts Via Src Family Kinases", Am JRespir Cell Mol Biol, (20090000), vol. 40, no. 2, pages 231 - 8 | - PHIPPS et al., "Differential Expression of Interleukin 1 Alpha by Thy-1+ and Thy-1- Lung Fibroblast Subpopulations: Enhancement of Interleukin 1 Alpha Production by Tumor Necrosis Factor-Alpha", Eur J Immunol, (19900000), vol. 20, no. 8, pages 1723 - 7 | - SHAN et al., "Thy-1 Attenuates Tnf-Alpha-Activated Gene Expression in Mouse Embryonic Fibroblasts Via Src Family Kinase", PLoS One, (20100000), vol. 5, no. 7, page ell662 | - BRUN et al., "Differential Activation of Adipogenesis by Multiple PPAR Isoforms", Genes Dev, (19960000), vol. 10, no. 8, pages 974 - 84, XP000577792 | - KIM; SPIEGELMAN, "Addl/Srebpl Promotes Adipocyte Differentiation and Gene Expression Linked to Fatty Acid Metabolism", Genes Dev, (19960000), vol. 10, no. 9, pages 1096 - 107 | - SPIEGELMAN et al., "Regulation of Adipogenesis and Energy Balance by PPARgamma and PGC-1", Int J Obes Relat Metab Disord, (20000000), vol. 24, no. 4, pages S8 - 10 | - TONTONOZ et al., "Regulation of Adipocyte Gene Expression and Differentiation by Peroxisome Proliferator Activated Receptor Gamma", Curr Opin Genet Dev, (19950000), vol. 5, no. 5, pages 571 - 6 | - TONTONOZ; SPIEGELMAN, "Fat and Beyond: The Diverse Biology of PPARgamma", Annu Rev Biochem, (20080000), vol. 77, doi:doi:10.1146/annurev.biochem.77.061307.091829, pages 289 - 312, XP055493833 DOI: http://dx.doi.org/10.1146/annurev.biochem.77.061307.091829 | - BARTEL, D.P., "Micrornas: Target Recognition and Regulatory Functions", Cell, (20090000), vol. 136, no. 2, doi:doi:10.1016/j.cell.2009.01.002, pages 215 - 33, XP055011377 DOI: http://dx.doi.org/10.1016/j.cell.2009.01.002 | - CARTHEW SONTHEIMER, "Origins and Mechanisms of Mirnas and Sirnas", Cell, (20090000), vol. 136, no. 4, doi:doi:10.1016/j.cell.2009.01.035, pages 642 - 55, XP055091221 DOI: http://dx.doi.org/10.1016/j.cell.2009.01.035 | - CHOI et al., "Anti-Diabetic Drugs Inhibit Obesity-Linked Phosphorylation of PPARgamma by Cdk5", Nature, (20100000), vol. 466, no. 7305, pages 451 - 6 | - AOUADI et al., "Inhibition of P38mapk Increases Adipogenesis from Embryonic to Adult Stages", Diabetes, (20060000), vol. 55, no. 2, pages 281 - 9 | - BURNS; VANDEN HEUVEL, "Modulation of PPAR Activity Via Phosphorylation", Biochim Biophys Acta, (20070000), vol. 1771, no. 8, doi:doi:10.1016/j.bbalip.2007.04.018, pages 952 - 60, XP022189880 DOI: http://dx.doi.org/10.1016/j.bbalip.2007.04.018 | - ENGELMAN et al., "Specific Inhibitors of P38 Mitogen-Activated Protein Kinase Block 3T3-L1 Adipogenesis", JBiol Chem, (19980000), vol. 273, no. 48, doi:doi:10.1074/jbc.273.48.32111, pages 32111 - 20, XP008124632 DOI: http://dx.doi.org/10.1074/jbc.273.48.32111 | - HU et al., "Inhibition of Adipogenesis Through Map Kinase-Mediated Phosphorylation of PPARgamma", Science, (19960000), vol. 274, no. 5295, doi:doi:10.1126/science.274.5295.2100, pages 2100 - 3, XP055000069 DOI: http://dx.doi.org/10.1126/science.274.5295.2100 | - PRUSTY et al., "Activation of MEK/ERK Signaling Promotes Adipogenesis by Enhancing Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma) and C/EBPalpha Gene Expression During the Differentiation of 3T3-L1 Preadipocytes", J Biol Chem, (20020000), vol. 277, no. 48, pages 46226 - 32 | - CHEN et al., "Meox2 Regulates Nuclear Factor-Kappab Activity in Vascular Endothelial Cells through Interactions with P65 and Ikappabbeta", Cardiovascular Research, (20100000), vol. 87, no. 4, pages 723 - 31 | - MANDEVILLE et al., "Impact of the Loss of Hoxa5 Function on Lung Alveogenesis", American Journal of Pathology, (20060000), vol. 169, no. 4, pages 1312 - 27 | - URBICH et al., "Role of Micrornas in Vascular Diseases, Inflammation, and Angiogenesis", Cardiovasc Res, (20080000), vol. 79, no. 4, doi:doi:10.1093/cvr/cvn156, pages 581 - 8, XP002559946 DOI: http://dx.doi.org/10.1093/cvr/cvn156 |